A new type of whole-body magnetic resonance imaging (MRI) test could be an alternative to standard positron emission tomography/computed tomography (PET/CT) imaging for assessing cancer in children and young adults, but without exposure to ...
Tags: MRI, radiation, tumour visibility
US-based biopharmaceutical company Immunomedics has announced the issuance of a US patent to its majority-owned subsidiary, IBC Pharmaceuticals, for ‘Novel Strategies for Improved Cancer Vaccines’. The new patent concerns ...
Oncology-focused drug development company Curis has secured US patent protecting intellectual property rights of its phosphoinositide 3-kinase (PI3K) - histone deacetylase (HDAC) inhibitor, CUDC-907. The patent covers the method of ...
Tags: Health&Medicine, Curis, US
Onco Therapies,a wholly owned subsidiary of Strides Arcolab,has received US Food and Drug Administration approval for Cisplatin injection. Cisplatin is a chemotherapy drug used to treat various types of cancers,including ...
Tags: Onco Therapies, Strides Arcolab, Cisplatin injection, chemotherapy drug
The European Commission (EC) has awarded a conditional marketing authorization approval for Cell Therapeutics' Pixuvri (pixantrone) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive ...
Tags: marketing authorization, pharmaceutical product, Pixuvri
Lixte Biotechnology, a cancer drug discovery company, has received a notice of allowance from the USPTO for its histone deacetylase inhibitor (HDACi), LB-201, and other structural homologs. Lixte founder and president John Kovach said ...
Tags: USPTO, cancer treatment, clinical technology, pharmaceutical product